Hormonal
Exercise stimulates the release of 'exerkines' (signaling molecules like IL-6, 12,13-diHOME, and musclin) that mediate systemic health benefits, including improved cardiac function and metabolic flexibility.
Engaging in regular exercise triggers the release of beneficial signaling molecules (exerkines) from your muscles, fat, and liver that protect your heart and metabolism. You don't need to manage these molecules directly; consistent physical activity is the key to activating them.
We subsequently focus on exercise-stimulated circulating biochemicals (“exerkines”) as a paradigm for understanding the global health circuitry of exercise, and discuss important concepts in this emerging field before highlighting exerkines relevant in cardiovascular health and disease.
Why this rating
The paper is a review of emerging research, noting that 'exact tissue sources of many of the exercise-induced plasma biochemicals remain uncertain'.
Source
Exercise, exerkines, and cardiometabolic health: from individual players to a team sport
Jeremy Robbins et al. · Journal of Clinical Investigation · 2023
DOI 10.1172/jci168121
More from this paper
- Regular exercise prevents and treats cardiometabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease, through pleiotropic effects on cardiorespiratory fitness and metabolic homeostasis.Good
- High-volume and high-intensity exercise may increase the risk of atrial fibrillation (AF) in athletes, suggesting a J-shaped relationship between exercise volume and AF risk.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →